Literature DB >> 8811306

Anemia of malignancy.

E P Frenkel1, R L Bick, C J Rutherford.   

Abstract

Anemia is a common association of malignant disease. It may be the first diagnostic clue to an underlying malignant disease, it may contribute to the patient's symptoms from the disease, and it may affect treatment decisions. It is important to recognize that a number of underlying mechanisms may contribute to the anemia, and to exclude those that are treatable. The recognition that tumor-associated cytokine production is a major factor in the anemia of malignancy, and that recombinant EPO can overcome this suppression, are major steps forward.

Entities:  

Mesh:

Year:  1996        PMID: 8811306     DOI: 10.1016/s0889-8588(05)70373-7

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

1.  Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients.

Authors:  N Charuruks; N Voravud; W Limpanasithikul
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease.

Authors:  Stephen L Seliger; Amy D Zhang; Matthew R Weir; Loreen Walker; Van Doren Hsu; Afshin Parsa; Clarissa J Diamantidis; Jeffrey C Fink
Journal:  Kidney Int       Date:  2011-03-09       Impact factor: 10.612

3.  Single measurement of hemoglobin predicts outcome of HCC patients.

Authors:  Fabian Finkelmeier; Dominik Bettinger; Verena Köberle; Michael Schultheiß; Stefan Zeuzem; Bernd Kronenberger; Albrecht Piiper; Oliver Waidmann
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.